SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc.

August 18, 2014 08:00 ET

PetLife Comments on Fox News Report of Scorpion Venom Cancer Benefits; Fox: "The Fact That This Has Worked Beautifully in Dogs That Have Cancer..."

BEVERLY HILLS, CA--(Marketwired - Aug 18, 2014) - PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID), today reported Fox News has published a story, dated July 23, titled, "Doctor Explains How Scorpion Venom Could Help Fight Cancer."

Highlights from the print story include: A doctor believes he has come up with a new way to locate cancer cells: with scorpion venom. The idea is for patients to be injected with a protein found in the venom that creates a fluorescent "tumor paint" around the borders of a cancerous mass.

Dr. James Olson, pediatric oncologist at Seattle Children's Hospital, joined Jenna Lee on Happening Now to discuss his trailblazing research. Olson -- who had a very difficult time getting grants for his study before private investors funded his team -- said that, following a difficult treatment with a 17-year-old cancer patient, a colleague asked him to come up with a solution when the best tools available simply aren't enough. "(He) asked me if my team could create a molecule that would make the cancer light up, so that surgeons can see what is cancer and what is not cancer."

The story goes on to say, "The fact that this has worked beautifully in dogs that have cancer and we've been testing it in human cancers grown in mice tells me it's not an unreasonable hope," he said.

Jenna asked Olson how he could be sure that the injection would not harm the patient. Olson responded that scorpion toxins contain thousands of proteins and he's working with one that has no known toxicity in humans or mammals. "We chose this one because it binds to a target that is on cancer cells, but isn't present on the surface of normal cells..."

The entire print story,and video interview with Dr. Olson is available at:

Commenting on the article, Arthur G. Mikaelian, Ph.D., PetLife Founder and CEO, said, "We are gratified to see that Dr. Olson, a respected American oncologist, is pushing forward with research that further confirms the effectiveness of Scorpion venom for treating cancer in humans and pets.

"We have dedicated ten years of research and development to developing Blue Scorpion venom into the current patented formula and its polarization process which culminated in Escozine for humans, which our sister company, Medolife, has successfully marketed in 40 countries for the past six years. That same formula and polarization process is in Escozine for Pets™, which we are now producing in a California FDA approved lab for retail launch next month.

"Western medicine remains resistant to innovative approaches to preventing and treating cancer, as Dr. Olson reports he had a 'very difficult time getting grants before private investors funded his team,' Dr. Mikaelian added. "I understand this all too well, and I congratulate him on his perseverance. For the same reasons, much of the clinical research on Escozine has been conducted to embrace innovative alternatives to conventional chemotherapy."

PetLife provides highlights of, and links to, the above news article for informational purposes only, as a courtesy to our shareholders. The Company disclaims any responsibility or liability for the accuracy of, or opinions expressed in, these and all other media articles.

About Petlife Pharmaceuticals
PetLife ( is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and a spinoff of Medolife Corp.

PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.

Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact Information